Open AccessCardiac contractility modulation therapy in elderly patients with chronic heart failure: results of the 12-month follow-up
Author(s) -
I. A. Chugunov,
К. В. Давтян,
А. Г. Топчян,
Н. А. Миронова,
Elena Gupalo
Publication year - 2021
Publication title -
vestnik aritmologii
Language(s) - English
Resource type - Journals
eISSN - 2658-7327
pISSN - 1561-8641
DOI - 10.35336/va-2021-2-5-10
Subject(s) - medicine , heart failure , ejection fraction , decompensation , cardiology , contractility , observational study
Aim. This study aimed to evaluate the efficacy and safety of cardiac contractility modulation (CCM) therapy in elderly patients with heart failure with reduced ejection fraction (HFrEF). Methods . Sixteen patients older than 65 years old (median age 70 years) undergoing CCM Optimizer (Impulse Dynamics) device implantation due to HFrEF (NYHA class II - 9 (56%), III - 4 (25%), IV - 3 (19%)) were enrolled in this two-center observational study. Before implantation 6-minute walk test (6MWT), transthoracic echocardiography (TTE) was performed on all patients, and NTproBNP levels were assessed. The follow-up duration was 12 months with 2, 6, 12-month follow-up visits. Control 6MWT, TTE and NTproBNP tests were performed at 6-month and 12-month follow-up visits. Results. Two patients died during follow-up due to HF decompensation. The remaining patients showed a significant improvement in 6MWT (350 m vs 402.5 m, p=0,01). We also noted a tendency towards the left ventricular EF improvement (33% vs 40%, p=0,2) and lower values of NTproBNP levels (1112 pg/ml vs 527 pg/ml, p=0,19). Conclusion. CCM therapy is a safe and efficient additional treatment option to manage elderly patients with HFrEF for reducing signs and symptoms of HF.